Vividion Therapeutics Announces Formation of Scientific Advisory Board pressreleasepoint.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from pressreleasepoint.com Daily Mail and Mail on Sunday newspapers.
E-Mail
IMAGE: The 2021 John Dystel Prize for Multiple Sclerosis Research goes to Vijay K. Kuchroo, DVM, PhD, the Samuel Wasserstrom Professor of Neurology at Harvard Medical School, for outstanding research contributions. view more
Credit: Brigham and Women s Hospital
NEW YORK, April 13, 2021 Vijay K. Kuchroo, DVM, PhD, the Samuel Wasserstrom Professor of Neurology at Harvard Medical School, has been selected as the 2021 recipient of the John Dystel Prize for Multiple Sclerosis Research.
A graduate of Veterinary Medicine from the College of Veterinary Medicine in Hisar, India, who earned a PhD in pathology at the University of Queensland in Brisbane Australia, Kuchroo is Senior Scientist at Brigham and Women s Hospital, and Co-director of the Center for Infection and Immunity, Brigham Research Institute, Boston. He is a member of the Broad Institute, and a participant in a Klarman Cell Observatory project that focuses on T cell differentiation and is the founding
Share this article
Share this article
CAMBRIDGE, Mass., Jan. 7, 2021 /PRNewswire/ Senda Biosciences, a Flagship Pioneering company creating novel categories of medicines based on Intersystems Biology, today announced the formation of its Scientific Advisory Board (SAB). Senda s SAB is composed of leading experts across immunology, microbiology, biochemistry, and neurology, and will collaborate with Senda s leadership to support and advance the new research discipline of Intersystems Biology. This discipline focuses on how molecular connections among botanical, bacterial, and human cells coevolved over millennia define health and disease. We are thrilled to have attracted some of the brightest minds in their fields to our SAB, says Guillaume Pfefer, PhD, chief executive officer of Senda. The deep expertise of the SAB will be pivotal to the advancement of our novel approach to medicines development, rooted in an unparalleled understanding of interspecies molecular connections.